IL166371A0 - Benzimidazole derivatives and their use as prodrugs of proton pump inhibitor - Google Patents

Benzimidazole derivatives and their use as prodrugs of proton pump inhibitor

Info

Publication number
IL166371A0
IL166371A0 IL16637105A IL16637105A IL166371A0 IL 166371 A0 IL166371 A0 IL 166371A0 IL 16637105 A IL16637105 A IL 16637105A IL 16637105 A IL16637105 A IL 16637105A IL 166371 A0 IL166371 A0 IL 166371A0
Authority
IL
Israel
Prior art keywords
prodrugs
proton pump
pump inhibitor
benzimidazole derivatives
bioavailability
Prior art date
Application number
IL16637105A
Other languages
English (en)
Original Assignee
Winston Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Winston Pharmaceuticals Llc filed Critical Winston Pharmaceuticals Llc
Publication of IL166371A0 publication Critical patent/IL166371A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
IL16637105A 2002-07-19 2005-01-18 Benzimidazole derivatives and their use as prodrugs of proton pump inhibitor IL166371A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39745902P 2002-07-19 2002-07-19
PCT/US2003/022419 WO2004009583A2 (en) 2002-07-19 2003-07-15 Benzimidazole derivatives and their use as prodrugs of proton pump inhibitor

Publications (1)

Publication Number Publication Date
IL166371A0 true IL166371A0 (en) 2006-01-16

Family

ID=30771064

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16637105A IL166371A0 (en) 2002-07-19 2005-01-18 Benzimidazole derivatives and their use as prodrugs of proton pump inhibitor

Country Status (23)

Country Link
US (3) US6897227B2 (pt)
EP (1) EP1556371B1 (pt)
JP (1) JP4463103B2 (pt)
KR (2) KR100788778B1 (pt)
AT (1) ATE323695T1 (pt)
AU (1) AU2003259154B2 (pt)
BR (1) BR0312802A (pt)
CA (1) CA2492718C (pt)
CO (1) CO5690576A2 (pt)
DE (1) DE60304726T2 (pt)
DK (1) DK1556371T3 (pt)
ES (1) ES2263028T3 (pt)
HK (1) HK1079207A1 (pt)
IL (1) IL166371A0 (pt)
MX (1) MXPA05000657A (pt)
NO (1) NO20050801L (pt)
NZ (1) NZ538221A (pt)
PL (1) PL375255A1 (pt)
PT (1) PT1556371E (pt)
RU (1) RU2292342C2 (pt)
TW (1) TW200502231A (pt)
WO (1) WO2004009583A2 (pt)
ZA (1) ZA200501116B (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6852739B1 (en) * 1999-02-26 2005-02-08 Nitromed Inc. Methods using proton pump inhibitors and nitric oxide donors
EP1534278A4 (en) * 2002-08-01 2006-09-06 Nitromed Inc NITROSED PROTONATE PUMP INHIBITORS, COMPOSITIONS AND USE METHOD
PL379542A1 (pl) * 2003-07-15 2006-10-02 Allergan, Inc. Sposób wytwarzania izomerycznie czystych proleków inhibitorów pompy protonowej
US20050075371A1 (en) * 2003-10-03 2005-04-07 Allergan, Inc. Methods and compositions for the oral administration of prodrugs of proton pump inhibitors
WO2005039640A1 (en) * 2003-10-03 2005-05-06 Allergan Inc. Compositions comprising trefoil factor family peptides and/or mucoadhesives and proton pump inhibitor prodrugs
US20070161679A1 (en) * 2004-02-18 2007-07-12 Allergan, Inc. Method and compositions for the intravenous administration of compounds related to proton pump inhibitors
BRPI0507784A (pt) * 2004-02-18 2007-07-17 Allergan Inc métodos e composições para a administração de pró-fármacos de inibidores da bomba de prótons
EP1722794A1 (en) * 2004-03-11 2006-11-22 Allergan, Inc. Methods and compositions for the treatment of conditions related to gastric acid secretion
US7176319B2 (en) 2004-04-28 2007-02-13 Hetero Drugs Limited Process for substituted sulfoxides
WO2007073301A1 (en) * 2005-12-23 2007-06-28 Astrazeneca Ab Benzoimidazole derivatives as prodrugs of proton pump inhibitors
US20070265311A1 (en) * 2006-01-10 2007-11-15 Rubino Mark P Therapeutic Salt Compositions and Methods
CA2649946A1 (en) * 2006-05-09 2007-11-15 Astrazeneca Ab New sterilized parenteral formulation
US20070293543A1 (en) * 2006-06-19 2007-12-20 Edward Lee THRESHOLD BLOOD OMEPRAZOLE CONCENTRATION IS 50 NG/ML FOR THE MAINTENANCE OF INTRAGASTRIC pH OF AT LEAST 4.0 AFTER ORAL DOSING WITH CMA-OMEPRAZOLE, AGN 201904-Z
WO2008036201A1 (en) * 2006-09-19 2008-03-27 Alevium Pharmaceuticals, Inc. Prodrugs of proton pump inhibitors including the 1h-imidazo[4,5-b] pyridine moiety
US20100113524A1 (en) * 2006-09-19 2010-05-06 Garst Michael E Prodrugs of proton pump inhibitors including the (1h-pyrrol-1-yl)-1h-benzimidazole moiety
KR20090035195A (ko) * 2007-10-05 2009-04-09 엘지전자 주식회사 플라즈마 디스플레이 장치
WO2009044976A1 (en) * 2007-10-05 2009-04-09 Lg Electronics Inc. Plasma display device
KR100895333B1 (ko) * 2007-11-01 2009-05-07 엘지전자 주식회사 플라즈마 디스플레이 패널의 구동 방법 및 그를 이용한플라즈마 디스플레이 장치
WO2012051036A1 (en) 2010-10-11 2012-04-19 Merck Sharp & Dohme Corp. Quinazolinone-type compounds as crth2 antagonists
EP2661265B1 (en) 2010-12-23 2017-03-08 Merck Sharp & Dohme Corp. Quinolines and aza-quinolines as crth2 receptor modulators
MX2013007295A (es) 2010-12-23 2013-08-26 Merck Sharp & Dohme Quinoxalinas y aza-quinoxalinas como moduladores del receptor de crth2.
CN107405338A (zh) * 2015-01-09 2017-11-28 加州大学评议会 用于治疗胃肠道感染的组合物和方法
CN108997177A (zh) * 2018-09-04 2018-12-14 邵阳学院 一种微波促进n-苯磺酰基硝基苯胺类化合物合成的方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US430042A (en) * 1890-06-10 Valve
SE416649B (sv) 1974-05-16 1981-01-26 Haessle Ab Forfarande for framstellning av foreningar som paverkar magsyrasekretionen
SE7804231L (sv) 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
JPS6150978A (ja) 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
IL76839A (en) 1984-10-31 1988-08-31 Byk Gulden Lomberg Chem Fab Picoline derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same
SE8505112D0 (sv) 1985-10-29 1985-10-29 Haessle Ab Novel pharmacological compounds
US4758597A (en) 1987-05-15 1988-07-19 University Patents, Inc. Carenadiol and derivatives
US4965269A (en) 1989-12-20 1990-10-23 Ab Hassle Therapeutically active chloro substituted benzimidazoles
US5045522A (en) 1990-03-27 1991-09-03 Phillips Petroleum Company Absorption composition comprising zinc titanate for removal of hydrogen sulfide from fluid streams
JP3049367B2 (ja) 1990-06-20 2000-06-05 アストラゼネカ・アクチエボラーグ ジアルコキシ−ピリジニル−ベンズイミダゾール誘導体、その製造方法およびそれを含む医薬
SE9301830D0 (sv) 1993-05-28 1993-05-28 Ab Astra New compounds
CA2192202A1 (en) * 1994-06-10 1995-12-21 Bernhard Kohl Substituted arylalkylthioalkylthiopyridines for use in the control of helicobacter bacteria
US5708017A (en) 1995-04-04 1998-01-13 Merck & Co., Inc. Stable, ready-to-use pharmaceutical paste composition containing proton pump inhibitors
ATE231857T1 (de) 1998-08-10 2003-02-15 Winston Pharmateuticals Llc Prodrugs für proton-pump-inhibitoren
US6093734A (en) 1998-08-10 2000-07-25 Partnership Of Michael E. Garst, George Sachs, And Jai Moo Shin Prodrugs of proton pump inhibitors
US6215004B1 (en) * 1998-08-12 2001-04-10 Emory University Method of manufacture of 1,3-oxathiolane nucleosides
SE0002476D0 (sv) 2000-06-30 2000-06-30 Astrazeneca Ab New compounds
US6599167B2 (en) 2000-09-27 2003-07-29 Glenn Waltz Game call holder and amplifying device
EP1334971A4 (en) * 2000-10-12 2004-05-12 Takeda Chemical Industries Ltd BENZIMIDAZOLE COMPOUNDS, METHOD FOR THE PRODUCTION AND USE THEREOF

Also Published As

Publication number Publication date
CO5690576A2 (es) 2006-10-31
RU2005105564A (ru) 2005-10-10
EP1556371B1 (en) 2006-04-19
JP4463103B2 (ja) 2010-05-12
NZ538221A (en) 2006-11-30
WO2004009583A2 (en) 2004-01-29
CA2492718A1 (en) 2004-01-29
DE60304726T2 (de) 2007-08-09
US20040102484A1 (en) 2004-05-27
AU2003259154C1 (en) 2004-02-09
AU2003259154A1 (en) 2004-02-09
US20050143423A1 (en) 2005-06-30
AU2003259154B2 (en) 2006-12-07
CA2492718C (en) 2010-12-21
MXPA05000657A (es) 2005-08-19
EP1556371A2 (en) 2005-07-27
DK1556371T3 (da) 2006-08-21
KR20050047078A (ko) 2005-05-19
JP2005536519A (ja) 2005-12-02
PT1556371E (pt) 2006-09-29
RU2292342C2 (ru) 2007-01-27
US6897227B2 (en) 2005-05-24
ES2263028T3 (es) 2006-12-01
KR20070005029A (ko) 2007-01-09
NO20050801L (no) 2005-02-15
PL375255A1 (en) 2005-11-28
KR100788778B1 (ko) 2007-12-27
WO2004009583A3 (en) 2004-03-18
HK1079207A1 (en) 2006-03-31
KR100822981B1 (ko) 2008-04-16
BR0312802A (pt) 2005-04-19
ATE323695T1 (de) 2006-05-15
TW200502231A (en) 2005-01-16
ZA200501116B (en) 2006-11-29
DE60304726D1 (de) 2006-05-24
US20050182101A1 (en) 2005-08-18

Similar Documents

Publication Publication Date Title
HK1079207A1 (en) Benzimidazole derivatives and their use as prodrugs of proton pump inhibitor
CA2338311A1 (en) Prodrugs of the pyridyl methyl sulfinyl benzimidazoles
EA200800006A1 (ru) Триазолопиридины в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы типа i
NO20025590D0 (no) Fenylglycin-derivater
ATE465146T1 (de) 1h-indolderivate als hochselektive cyclooxygenase-2-inhibitoren
SE0202463D0 (sv) Novel compounds
TR200200579T2 (tr) Amino-tirazolpiridin türevleri.
MXPA05010000A (es) Derivados de p-diaminobenceno substituidos.
TNSN06220A1 (en) Benzimidazole derivatives
TR200002605T2 (tr) Nitrik oksit sentaz inhibitörleri olarak faydalı halojene amidino amino asit türevleri
MXPA05010521A (es) Inhibidores de cinasa de amida de bifenilcarboxilica p38.
ATE303384T1 (de) 1-biaryl-1,8-naphthyridin-4-one als phosphodieseterase-inhibitoren
MXPA05010174A (es) Derivados de indol e indolina sustituidos.
EA200801200A1 (ru) ПРОИЗВОДНЫЕ ПИРАЗОЛИЗОХИНОЛИНМОЧЕВИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ p38 КИНАЗЫ
RS52315B (en) DIARYLMETHYL PIPERAZINE DERIVATIVES, THEIR PREPARATION AND THEIR USE
TW200420545A (en) 1-(4-benzyl-piperazin-1-yl)-3-phenyl-propenone derivatives
DE60027144D1 (de) Hydroxamsäure-derivate
TW200733963A (en) Cough inhibitor
MXPA05009282A (es) Derivados de anilina sustituidos.
DK1696911T3 (da) Intranasale sammensætninger
GB0308201D0 (en) Novel compounds
EE05241B1 (et) Distamtsiini a-halogenoakrlolderivaadi kasutamine
MXPA05006889A (es) Compuestos aromaticos como agentes anti-inflamatorios, inmunomoduladores y anti-proliferativos.
TR200302134T4 (tr) 2-metil-tiazolidin-2,4-dikarboksilik asit ve/veya bunun fizyolojik olarak uygun tuzlarının anti-kanser ajanları olarak kullanımı.
UA102376C2 (ru) Стойкая жидкая фармацевтическая композиция на основе тразодона